18 JUL 2003

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

G00002

(43) International Publication Date
26 October 2000 (26.10.2000)

PCT

(10) International Publication Number
WO 00/62657 A3

(51) International Patent Classification[7]: A61P 37/06, 37/04, 5/02, 5/24, A61K 38/09

(21) International Application Number: PCT/AU00/00329

(22) International Filing Date: 17 April 2000 (17.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PP9778 15 April 1999 (15.04.1999) AU

(71) Applicant *(for all designated States except US)*: MONASH UNIVERSITY [AU/AU]; Wellington Road, Clayton, Victoria 3168 (AU).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: BOYD, Richard, Lennox [AU/AU]; 60 Linacre Road, Hampton, Victoria 3188 (AU).

(74) Agent: F B RICE & CO; 139 Rathdowne Street, Carlton, Victoria 3053 (AU).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *With international search report*

(88) Date of publication of the international search report:
11 January 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

162162

WO 00/62657 A3

(54) Title: IMPROVEMENT OF T CELL MEDIATED IMMUNITY

(57) Abstract: The present invention provides a method of modifying the T-cell population makeup or increasing the number of T-cells in a subject having depressed or abnormal T-cell population or function, the method comprising disrupting sex steroid signalling to the thymus in the subject. The invention can be used to treat a subject suffering from a wide array of diseases, for example, cancer, HIV infection, autoimmunity and hypersensitivity. In addition, the present invention provides methods for enhancing an immune response to an antigen, treating an autoimmune disease, and decreasing a host-vs-graft reaction in a transplantation donor.